Cross-protection by MF59™-adjuvanted influenza vaccine:: Neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses

被引：104

作者：

Ansaldi, Filippo ^{[1
]}

Bacilieri, Sabrina ^{[1
]}

Durando, Paolo ^{[1
]}

Sticchi, Laura ^{[1
]}

Valle, Laura ^{[1
]}

Montomoli, Ernanuele ^{[2
]}

Icardi, Giancarlo ^{[1
]}

Gasparini, Roberto ^{[1
]}

Crovari, Pietro ^{[1
]}

机构：

[1] Univ Genoa, Dept Hlth Sci, CIRI IV, I-16100 Genoa, Italy

[2] Univ Siena, Expt Med & Publ Hlth, Dept Phytopathol, I-53100 Siena, Italy

来源：

VACCINE | 2008年 / 26卷 / 12期

关键词：

influenza; MF59 (TM); antigenic drift; cross-protection;

D O I：

10.1016/j.vaccine.2008.01.019

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Adjuvants enhance antibody response against vaccination. We compared the ability of MF59 (TM)-adjuvanted and non-adjuvanted subunit influenza vaccines, containing A/Wyoming/3/03(H3N2), to confer cross-protection against four consecutive drifted strains in the elderly. Neutralizing and haemagglutination-inhibiting antibody were measured. MF59 (TM)-adjuvanted vaccine induced a stronger booster response against A/Panama/2007/99(H3N2) than non-adjuvanted vaccine. A/Panama/2007/99(H3N2) circulated widely during the previous 5 years and was included in vaccines over four consecutive seasons. Broader serological protection against drifted strains that circulated 1 and 2 years after vaccination with A/Wyoming/3/03(H3N2) was observed with MF59 (TM)-adjuvanted vaccine. Thus, MF59 (TM)-adjuvanted vaccine confers greater immunogenicity than non-adjuvanted vaccines in vulnerable populations. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：1525 / 1529

页数：5

共 22 条

[1] Neutralizing and hemagglutination-inhibiting activities of antibodies elicited by the 2004-2005 influenza vaccine against drifted viruses
Ansaldi, F
Bacilieri, S
Banfi, F
Durando, P
Sticchi, L
Icardi, G
Gasparini, R
[J]. CLINICAL AND VACCINE IMMUNOLOGY, 2006, 13 (01) : 162 - 164
[2] New A/H3N2 influenza variant: a small genetic evolution but a heavy burden on the Italian population during the 2004-2005 season
Ansaldi, F
Icardi, G
Gasparini, R
Campello, C
Puzelli, S
Bella, A
Donatelli, I
Salmaso, S
Crovari, P
[J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2005, 43 (06) : 3027 - 3029
[3] Response of influenza vaccines against heterovariant influenza virus strains in adults with chronic diseases
Baldo, V.
Baldovin, T.
Floreani, A.
Fragapane, E.
Trivello, R.
[J]. JOURNAL OF CLINICAL IMMUNOLOGY, 2007, 27 (05) : 542 - 547
[4] NEUTRALIZATION ENZYME-IMMUNOASSAY FOR INFLUENZA-VIRUS
BENNE, CA
HARMSEN, M
DEJONG, JC
KRAAIJEVELD, CA
[J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1994, 32 (04) : 987 - 990
[5] Seroprotection rate, mean fold increase, seroconversion rate:: which parameter adequately expresses seroresponse to influenza vaccination?
Beyer, WEP
Palache, AM
Lüchters, G
Nauta, J
Osterhaus, ADME
[J]. VIRUS RESEARCH, 2004, 103 (1-2) : 125 - 132
[6] Influenza vaccine: The challenge of antigenic drift
Carrat, F.
Flahault, A.
[J]. VACCINE, 2007, 25 (39-40) : 6852 - 6862
[7] Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly
De Donato, S
Granoff, D
Minutello, M
Lecchi, G
Faccini, M
Agnello, M
Senatore, F
Verweij, P
Fritzell, B
Podda, A
[J]. VACCINE, 1999, 17 (23-24) : 3094 - 3101
[8] de Jong JC, 2000, J MED VIROL, V61, P94, DOI 10.1002/(SICI)1096-9071(200005)61:1&lt
[9] 94::AID-JMV15&gt
[10] 3.0.CO

← 1 2 3 →